Latest ExpreS2ion Biotechnologies News & Updates

See the latest news and media coverage for ExpreS2ion. We track all announcements, press releases, and industry mentions in real time, all in one place.

ExpreS2ion Biotechnologies (ExpreS2ion)

Clinical-stage immunotherapy biotechnology company

expres2ionbio.com

Headquarters: Horsholm, Denmark
Founded year: 2010
Company type: Public company
Number of employees: 20–50

Last updated Today

Latest news about ExpreS2ion Biotechnologies (ExpreS2ion)

In short: ExpreS2ion Biotechnologies reported financial losses for 2025 and Q1 2026, while successfully advancing clinical trials and securing capital.

Company announcements

June 5 ExpreS2ion

ExpreS2ion published its annual report for 2025

The report includes financial results and strategy, available on the company website.

June 1 ExpreS2ion

ExpreS2ion reviews Q1 progress across clinical, operational, financial fronts

CEO presented at BioStock Global Forum and Q1 results webcast; rights issue raised SEK 31.8 million.

May 26 ExpreS2ion

ExpreS2ion announces Annual General Meeting on 25 June 2026

The meeting will be held at Mindpark, Helsingborg, with postal voting options and proposals for incentive program and board re-election.

May 19 ExpreS2ion

ExpreS2ion updates ES2B-C001 Phase I programme and reports preliminary observations

The updated design adds a maintenance component and revised Phase II plan, with antibody responses in 9 of 9 patients and no safety concerns.

Media coverage

May 19 FinanzNachrichten

ExpreS2ion Biotech Holding AB: ExpreS2ion Updates ES2B-C001 Phase I Programme and Reports Additional Preliminary Immunogenicity and Safety Observations

Hørsholm, Denmark, 19 May 2026 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion"), a clinical-stage biotechnology company with a pipeline of novel immunotherapie...

April 7 FinanzNachrichten

ExpreS2ion Biotech Holding AB: The Board of Directors of ExpreS2ion has resolved on a rights issue of units of approximately SEK 53 million, primarily to advance its lead ...

Hørsholm, Denmark, 7 April 2026 - The Board of Directors of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") has today, on 7 April...

March 25 TradingView

ExpreS2ion reports consistent, durable anti-HER2 responses; advances ES2B-C001 Phase I after independent DSMB review — TradingView News

Hørsholm, Denmark, 25 March 2026 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of active...

February 26 MFN

ExpreS2ion Biotech Holding AB: EXPRES2ION ANNOUNCES THE BOARD OF DI...

Background and rationale ExpreS2ion is a biotechnology company focused on the development and application of advanced protein expression technologies for vaccines and immunotherapies targeting infectious...

Never miss news about ExpreS2ion

Track ExpreS2ion and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

ExpreS2ion competitors & trending companies

Browse news for competitors to ExpreS2ion and other trending companies.